StressCovidV1, Pmc, Checkpoint, bibRecord, 000558

COVID-19: immunopathology and its implications for therapy

Identifieur interne : 000558 ( Pmc/Checkpoint ); précédent : 000557; suivant : 000559

COVID-19: immunopathology and its implications for therapy

Auteurs : Xuetao Cao [République populaire de Chine]

Source :

Nature Reviews. Immunology [ 1474-1733 ] ; 2020.

RBID : PMC:7143200

Abstract

Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143200

DOI: 10.1038/s41577-020-0308-3
PubMed: 32273594
PubMed Central: 7143200

Affiliations:

République populaire de Chine

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 000014
to stream Pmc, to step Curation: 000014

Links to Exploration step

PMC:7143200

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: immunopathology and its implications for therapy</title>
<author><name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
<affiliation wicri:level="1"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9878 7032</institution-id>
<institution-id institution-id-type="GRID">grid.216938.7</institution-id>
<institution>Laboratory of Immunity and Inflammation,</institution>
<institution>College of Life Science, Nankai University,</institution>
</institution-wrap>
Tianjin, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tianjin</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0662 3178</institution-id>
<institution-id institution-id-type="GRID">grid.12527.33</institution-id>
<institution>Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences,</institution>
<institution>Chinese Academy of Medical Sciences,</institution>
</institution-wrap>
Beijing, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32273594</idno>
<idno type="pmc">7143200</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143200</idno>
<idno type="RBID">PMC:7143200</idno>
<idno type="doi">10.1038/s41577-020-0308-3</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000014</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000014</idno>
<idno type="wicri:Area/Pmc/Curation">000014</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000014</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000558</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000558</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">COVID-19: immunopathology and its implications for therapy</title>
<author><name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
<affiliation wicri:level="1"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9878 7032</institution-id>
<institution-id institution-id-type="GRID">grid.216938.7</institution-id>
<institution>Laboratory of Immunity and Inflammation,</institution>
<institution>College of Life Science, Nankai University,</institution>
</institution-wrap>
Tianjin, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tianjin</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0662 3178</institution-id>
<institution-id institution-id-type="GRID">grid.12527.33</institution-id>
<institution>Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences,</institution>
<institution>Chinese Academy of Medical Sciences,</institution>
</institution-wrap>
Beijing, China</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature Reviews. Immunology</title>
<idno type="ISSN">1474-1733</idno>
<idno type="eISSN">1474-1741</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="Par1">Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Huang, C" uniqKey="Huang C">C Huang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Xu, Z" uniqKey="Xu Z">Z Xu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Qin, C" uniqKey="Qin C">C Qin</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Zheng, M" uniqKey="Zheng M">M Zheng</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Shen, C" uniqKey="Shen C">C Shen</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Runfeng, L" uniqKey="Runfeng L">L Runfeng</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="brief-report"><pmc-dir>properties open_access</pmc-dir>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Rev Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat. Rev. Immunol</journal-id>
<journal-title-group><journal-title>Nature Reviews. Immunology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1474-1733</issn>
<issn pub-type="epub">1474-1741</issn>
<publisher><publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">32273594</article-id>
<article-id pub-id-type="pmc">7143200</article-id>
<article-id pub-id-type="publisher-id">308</article-id>
<article-id pub-id-type="doi">10.1038/s41577-020-0308-3</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Comment</subject>
</subj-group>
</article-categories>
<title-group><article-title>COVID-19: immunopathology and its implications for therapy</article-title>
</title-group>
<contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Cao</surname>
<given-names>Xuetao</given-names>
</name>
<address><email>caoxt@immunol.org</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label>
<institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9878 7032</institution-id>
<institution-id institution-id-type="GRID">grid.216938.7</institution-id>
<institution>Laboratory of Immunity and Inflammation,</institution>
<institution>College of Life Science, Nankai University,</institution>
</institution-wrap>
Tianjin, China</aff>
<aff id="Aff2"><label>2</label>
<institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0662 3178</institution-id>
<institution-id institution-id-type="GRID">grid.12527.33</institution-id>
<institution>Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences,</institution>
<institution>Chinese Academy of Medical Sciences,</institution>
</institution-wrap>
Beijing, China</aff>
</contrib-group>
<pub-date pub-type="epub"><day>9</day>
<month>4</month>
<year>2020</year>
</pub-date>
<fpage>1</fpage>
<lpage>2</lpage>
<permissions><copyright-statement>© Springer Nature Limited 2020</copyright-statement>
<license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
</license>
</permissions>
<abstract id="Abs1" abstract-type="Standfirst"><p id="Par1">Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.</p>
</abstract>
<abstract id="Abs2" abstract-type="web-summary"><p id="Par2">In the short time since SARS-CoV2 emerged, much has been learned about the immunopathology of the infection. Here, Xuetao Cao discusses what these early insights imply for drug discovery and clinical management.</p>
</abstract>
<kwd-group kwd-group-type="npg-subject"><title>Subject terms</title>
<kwd>Infection</kwd>
<kwd>Immunology</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
</noRegion>
<name sortKey="Cao, Xuetao" sort="Cao, Xuetao" uniqKey="Cao X" first="Xuetao" last="Cao">Xuetao Cao</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000558 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000558 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:7143200
   |texte=   COVID-19: immunopathology and its implications for therapy
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i   -Sk "pubmed:32273594" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021

	Serveur d'exploration Stress et Covid
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Stress et Covid

COVID-19: immunopathology and its implications for therapy

COVID-19: immunopathology and its implications for therapy

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki